Literature DB >> 18588355

Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study.

P Usharani1, A A Mateen, M U R Naidu, Y S N Raju, Naval Chandra.   

Abstract

BACKGROUND AND
OBJECTIVE: Hyperglycaemia leads to increased oxidative stress resulting in endothelial dysfunction. ACE inhibitors, antioxidants and HMG-CoA reductase inhibitors (statins) have been shown to improve endothelial function. The aim of this study was to compare the effects of NCB-02 (a standardized preparation of curcuminoids), atorvastatin and placebo on endothelial function and its biomarkers in patients with type 2 diabetes mellitus.
METHODS: A total of 72 patients with type 2 diabetes were randomized to receive NCB-02 (two capsules containing curcumin 150 mg twice daily), atorvastatin 10 mg once daily or placebo for 8 weeks. Endothelial function assessment was performed at baseline and post-treatment using digital volume plethysmography (salbutamol [albuterol] challenge test) to measure change in reflective index, an indicator of arterial vascular tone. Blood samples were similarly collected at baseline and post-treatment for estimations of malondialdehyde, endothelin-1 (ET-1), interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNFalpha). Pre-and post-treatment safety assessments were also conducted. ANOVA and paired t-test evaluations were used for comparison.
RESULTS: A total of 67 patients completed the study. At baseline, there was no significant difference in the various parameters tested. In all three groups, the change in reflective index at baseline was <6% as assessed by the salbutamol challenge test, indicating the presence of endothelial dysfunction. Compared with baseline, there was a significant improvement in endothelial function after treatment with atorvastatin (mean +/- SD: -3.63 +/- 3.17% vs -8.95 +/- 6.80%, respectively) and NCB-02 (-2.69 +/- 3.02% vs -8.19 +/- 5.73%, respectively). Similarly, patients receiving atorvastatin or NCB-02 showed significant reductions in the levels of malondialdehyde, ET-1, IL-6 and TNFalpha. No significant improvements were obtained in patients administered placebo.
CONCLUSION: NCB-02 had a favourable effect, comparable to that of atorvastatin, on endothelial dysfunction in association with reductions in inflammatory cytokines and markers of oxidative stress. Further studies are needed to evaluate the potential long-term effects of NCB-02 and its combination with other herbal antioxidants.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18588355     DOI: 10.2165/00126839-200809040-00004

Source DB:  PubMed          Journal:  Drugs R D        ISSN: 1174-5886


  43 in total

Review 1.  Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases.

Authors:  Ajaikumar B Kunnumakkara; Devivasha Bordoloi; Ganesan Padmavathi; Javadi Monisha; Nand Kishor Roy; Sahdeo Prasad; Bharat B Aggarwal
Journal:  Br J Pharmacol       Date:  2016-10-21       Impact factor: 8.739

Review 2.  Therapeutic roles of curcumin: lessons learned from clinical trials.

Authors:  Subash C Gupta; Sridevi Patchva; Bharat B Aggarwal
Journal:  AAPS J       Date:  2012-11-10       Impact factor: 4.009

3.  Curcumin improves treatment outcome of Takayasu arteritis patients by reducing TNF-α: a randomized placebo-controlled double-blind clinical trial.

Authors:  Nan Shao; Huixin Jia; Yiwen Li; Jingying Li
Journal:  Immunol Res       Date:  2017-08       Impact factor: 2.829

Review 4.  New mechanisms and the anti-inflammatory role of curcumin in obesity and obesity-related metabolic diseases.

Authors:  Adeeb Shehzad; Taewook Ha; Fazli Subhan; Young Sup Lee
Journal:  Eur J Nutr       Date:  2011-03-27       Impact factor: 5.614

Review 5.  Discovery of curcumin, a component of golden spice, and its miraculous biological activities.

Authors:  Subash C Gupta; Sridevi Patchva; Wonil Koh; Bharat B Aggarwal
Journal:  Clin Exp Pharmacol Physiol       Date:  2012-03       Impact factor: 2.557

6.  Co-delivery of natural metabolic inhibitors in a self-microemulsifying drug delivery system for improved oral bioavailability of curcumin.

Authors:  Alex E Grill; Brenda Koniar; Jayanth Panyam
Journal:  Drug Deliv Transl Res       Date:  2014-08       Impact factor: 4.617

7.  A Systematic Review and Meta-analysis of Randomized Controlled Trials on the Effects of Turmeric and Curcuminoids on Blood Lipids in Adults with Metabolic Diseases.

Authors:  Fen Yuan; Hui Dong; Jing Gong; Dingkun Wang; Meilin Hu; Wenya Huang; Ke Fang; Xin Qin; Xin Qiu; Xueping Yang; Fuer Lu
Journal:  Adv Nutr       Date:  2019-09-01       Impact factor: 8.701

8.  Effect of Curcumin on Glycemic Control in Patients with Type 2 Diabetes: A Systematic Review of Randomized Clinical Trials.

Authors:  Atena Mahdavi; Sajjad Moradi; Gholamreza Askari; Bijan Iraj; Thozhukat Sathyapalan; Paul C Guest; Mohammad Bagherniya; Amirhossein Sahebkar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 9.  Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers.

Authors:  Bharat B Aggarwal; Subash C Gupta; Bokyung Sung
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

10.  Efficacy of a novel water-soluble curcumin derivative versus sildenafil citrate in mediating erectile function.

Authors:  A M S Zaahkouk; M T Abdel Aziz; A M Rezq; H M Atta; H H Fouad; H H Ahmed; D Sabry; M H Yehia
Journal:  Int J Impot Res       Date:  2014-08-07       Impact factor: 2.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.